APASL STC 2026 Singapore

Programme

Day 0, Thursday 9th July 2026 – Pre-Conference Workshops

Pre-Conference Workshop 1: Endohepatology	AM: Management of portal hypertensive complications Variceal bleeding Portal hypertensive gastropathy GAVE EUS guided interventions Advances in endohepatology Pancreatobiliary endoscopy in cirrhotic patients Pancreatobiliary endoscopy in transplant patients PM: Hands on workshop
Pre-Conference Workshop 2: Molecular Session	Basic and translational science in chronic liver disease workshop

Day 1, Friday, 10th July 2026, APASL STC 2026

Symposium 1: HCC screening and Detection	Aetiology specific considerations in HCC surveillance Recompensation and surveillance Blood based biomarkers for HCC - can we escape scans Abbreviated MRI and novel imaging biomarkers Q&A
Opening Ceremony
Tea Symposium
Symposium 2: HCC management	Pearls and pitfalls of ICI / systemic therapy in the cirrhotic and decompensated patient Pre-transplant ICI Intermediate stage HCC - Y90 Intermediate stage HCC - SBRT Q&A
Lunch Symposium
Symposium 3: Autoimmune and cholestatic disease	Preventing and managing PBC cirrhosis Prognostication of PSC cirrhosis: optimizing outcomes and transplant consideration Treatment considerations in the AIH patient with compensated cirrhosis Over-overlap: the importance of interface activity - case discussion based Q&A
Tea Symposium
Symposium 4: Other aetiologies	Cryptogenic cirrhosis - are we missing an underlying aetiology? Hyperferrtinemia in the Asian cirrhotic patient Should my CLD patient have genetic testing? Complex case discussion 1 Q&A

Day 2, Saturday, 11th July 2026, APASL STC 2026

Symposium 5: Viral Hepatitis	Recompensation in viral Hepatitis Management of the MASH-HBV cirrhotic patient HBV ACLF - an Asian approach to transplant considerations Antiviral considerations in the management of viral associated HCC's Q&A
Plenary / State of the Art
Tea Symposium
Symposium 6: Metabolic Disease / Alcohol	Liver directed treatments for the MASH patient – preventing and reversing cirrhosis Holistic management of the MASH cirrhosis patient Steroids therapy in AAH - PRO Steroids therapy in AAH - CON Q&A
Lunch Symposium
Symposium 7: Portal Hypertension	Implications of aetiology on portal hypertensive complications and its management Albumin use case in cirrhosis POCUS: use case in cirrhosis Choice and timing of vasoactive agents in portal hypertensive complications Q&A
Tea Symposium
Symposium 8: Complications	The confused cirrhotic patient Bleeding and coagulation in the cirrhotic patient Optimising outcomes in PVT : anticoagulation, PVR-TIPS, or shunt surgery SBP prophylaxis: are we breeding resistance? Q&A

Day 3, Sunday, 12th July 2026, GI Hep

Symposium 9: IBD	The 2026 IBD Decision Playbook In light of the changing landscape of biologics; how to choose the best agent - a guide that clinician can use on Monday morning Treat-to-Target:E volving Landscape - The role of IUS in modern Management of IBD When Context Changes the Decision - Navigating IBD care in pregnancy Immune Checkpoint Inhibitor Colitis: When IBD Rules Don't Apply ICI management - practical guide to recognising, diagnosing and managing ICI colitis
Tea Symposium
Symposium 10: Nutrition / Microbiome	Hocus Pocus in IBS dietary management Dietary intervention for metabolic condition Microbiome modulation for immunotherapy or chemotherapy augmentation Microbiome post bariatric surgery Q&A
Lunch Symposium
Symposium 11: Pancreatobiliary	Approach to Biliary Strictures: 2026 AI in ERCP/Cholangioscopy EUS Guided Biliary Drainage EUS Guided Vascular Intervention Q&A
Tea Symposium
Symposium 12: Endoscopy	Premalignant gastric conditions – Guidelines from the East to the West Practical tips on what I’m supposed to do in Singapore Should I use AI for my colonoscopies? – Comparing consensus from different continents Endoscopy in a Warming World: Designing Climate Responsible Practice Q&A